The Partnership Between Absci and AstraZeneca

Absci, a leader in generative AI antibody discovery, has partnered with AstraZeneca to utilize AI in the development of a new cancer treatment.

Collaboration Details

• The collaboration aims to leverage Absci’s Integrated Drug Creation platform, combined with AstraZeneca’s expertise in oncology, to expedite the discovery of a potentially game-changing cancer therapy.
• The agreement includes an upfront commitment, substantial R&D funding, milestone payments, and royalties on future product sales.
• Absci will deploy its generative AI technology to design a therapeutic candidate antibody tailored for a specific oncology target.

Integrated Drug Creation Platform

Absci’s platform combines generative AI and scalable lab technologies to generate proprietary data by scrutinizing millions of protein-protein interactions.

This data fuels Absci’s proprietary AI models, facilitating the design of antibodies that are later validated through lab experiments, completing the entire cycle within approximately six weeks.

Industry Leaders’ Comments

Sean McClain, Founder & CEO of Absci, expressed excitement about collaborating with AstraZeneca to design a therapeutic candidate antibody, while Puja Sapra, PhD, SVP of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, commented on utilizing Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.

Conclusion

The collaboration signifies the potential for AI to revolutionize drug discovery, especially in the field of oncology.